Darren Carroll, Vice President Corporate Business Development, Eli Lilly, will talk about how Lilly is pioneering a new capital efficient model to develop therapeutics by partnering with venture capital firms and leveraging resources. Rather than build complete companies around a single molecule, Lilly’s VC partners set up virtual structures that can utilize Lilly development and avoid sizable overhead. Darren will talk about this program as well as Lilly Ventures, the company’s corporate venture capital fund, which he oversees. He will give his perspective on investment in early stage life science ventures.
Sponsored by WilmerHale.
Register here: https://febspeakerseries.eventbrite.com